ZeroOCD: Learn to Overcome Contamination OCD With Your Smartphone
Condition(s) studied
Investigational drug(s) / intervention(s)
ZeroOCD: The ZeroOCD app contains the following components: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure with AR, re-exposure with AR, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention
Videoconferencing CBT: Videoconferencing CBT contains the following chapters: psychoeducation, detecting obsessive thoughts, coping with obsessions, goal setting, fear curve explanation, exposure hierarchy, exposure in real-life, re-exposure in real life and relapse prevention
Study summary
This study is a three-arm randomized controlled trial designed to evaluate the efficacy of a smartphone-based augmented reality (AR) cognitive behavioral therapy (CBT) app, called ZeroOCD, for individuals with elevated contamination-related obsessive-compulsive disorder (OCD) symptoms. The AR-CBT app will be compared to both an active control condition (manualized CBT via videoconferencing) and a waitlist control group.
Eligibility
Primary outcome measure(s)
- OCD Symptoms (Interview) — At baseline, At 10 weeks, At 20 weeks (only WL condition) At 24 weeks
Yale-Brown Obsessive Compulsive Scale (Y-BOCS): Change from baseline in the observer-rated severity of OCD symptoms. This is a 10-item, clinician-rated scale that provides separate subtotals for the severity of obsessions and compulsions. Total scores range from 0 to 40, with higher scores indicating more severe symptoms. The Y-BOCS is also used for the eligibility (mean score \> 7).
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| Thomas More Mechelen | Mechelen | Belgium | |
| Vrije Universiteit Amsterdam | Amsterdam | North Holland | |
| Stockholm University | Stockholm | Sweden | |
| UBERN | Bern | Switzerland |
More VU University of Amsterdam trials in the Netherlands
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07194473 on ClinicalTrials.gov ↗ ← All trials in the Netherlands